1623 Capital’s Taysha Gene Therapies TSHA Stock Holding History

1623 Capital’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-46,763	Closed	-$305K	–	52
2022 Q1	$305K	Buy	+46,763	New	+$350K	0.15%	45

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

1623 Capital's TSHA Position: Q2 2022 in Review

1623 Capital sold out of Taysha Gene Therapies (TSHA) in Q2 2022, closing a stake of 46,763 shares — an estimated $305K sold.

1623 Capital first reported a position in TSHA in Q1 2022 and held it in 1 quarter. The position peaked at $305K in Q1 2022. 59 funds tracked by Wall St. Rank hold TSHA as of Q2 2022.

1623 Capital reported no remaining Taysha Gene Therapies position as of Q2 2022 after selling out during the quarter.
1623 Capital sold 46,763 Taysha Gene Therapies shares in Q2 2022, an estimated $305K.
1623 Capital first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 1 quarter.
1623 Capital's Taysha Gene Therapies position peaked at $305K in Q1 2022.
59 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2022.

Based on 1623 Capital's 13F filing for Q2 2022, filed 12 Aug 2022.